Source:http://linkedlifedata.com/resource/pubmed/id/17435113
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0015533,
umls-concept:C0015982,
umls-concept:C0205245,
umls-concept:C0302148,
umls-concept:C0337112,
umls-concept:C0427008,
umls-concept:C0449774,
umls-concept:C0680730,
umls-concept:C0936012,
umls-concept:C1148554,
umls-concept:C1524075,
umls-concept:C1552644,
umls-concept:C1823153,
umls-concept:C2349976
|
pubmed:issue |
3
|
pubmed:dateCreated |
2007-7-23
|
pubmed:abstractText |
Activated coagulation factor XIII (FXIIIa) cross-links the gamma-chains of fibrin early in clot formation. Cross-linking of the alpha-chains occurs more slowly, leading to high molecular weight multimer formations that can also contain gamma-chains. To study the contribution of FXIIIa-induced gamma-chain cross-linking on fibrin structure and function, we created 2 recombinant fibrinogens (gammaQ398N/Q399N/K406R and gammaK406R) that modify the gamma-chain cross-linking process. In gammaK406R, gamma-dimer cross-links were absent, but FXIIIa produced a cross-linking pattern similar to that observed in tissue transglutaminase cross-linked fibrin(ogen) with mainly alpha-gamma cross-links. In Q398N/Q399N/K406R, cross-links with any gamma-chain involvement were completely absent, and only alpha-chain cross-linking occurred. Upon cross-linking, recombinant normal fibrin yielded a 3.5-fold increase in stiffness, compared with a 2.5-fold increase by alpha-chain cross-linking alone (gammaQ398N/Q399N/K406R). gammaK406R fibrin showed a 1.5-fold increase in stiffness after cross-linking. No major differences in clot morphology, polymerization, and lysis rates were observed, although fiber diameter was slightly lower in cross-linked normal fibrin relative to the variants. Our results show that gamma-chain cross-linking contributes significantly to clot stiffness, in particular through gamma-dimer formation; alpha-gamma hybrid cross-links had the smallest impact on clot stiffness.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
110
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
902-7
|
pubmed:dateRevised |
2007-12-3
|
pubmed:meshHeading |
pubmed-meshheading:17435113-Amino Acid Substitution,
pubmed-meshheading:17435113-Factor XIIIa,
pubmed-meshheading:17435113-Fibrin,
pubmed-meshheading:17435113-Humans,
pubmed-meshheading:17435113-Multiprotein Complexes,
pubmed-meshheading:17435113-Mutation, Missense,
pubmed-meshheading:17435113-Recombinant Proteins
|
pubmed:year |
2007
|
pubmed:articleTitle |
Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness.
|
pubmed:affiliation |
Academic Unit of Molecular Vascular Medicine, Leeds Institute for Genetics, Health and Therapeutics, Clarendon Way, University of Leeds, UK.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|